CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones
Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across ...
Buy Rating for Crispr Therapeutics AG: Strong Pipeline, Strategic Partnerships, and Financial Stability Drive Confidence
Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...
CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Lowered to $85.00 at Bank of America
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by Bank of America from $98.00 to $85.00 in ...
STAT5d
Scribe Therapeutics becomes latest CRISPR company to announce layoffs
Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...
Nordea Investment Management AB Increases Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)
Nordea Investment Management AB grew its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 4.4% in the ...
Crispr Therapeutics price target lowered to $85 from $98 at BofA
BofA analyst Alec Stranahan lowered the firm’s price target on Crispr Therapeutics (CRSP) to $85 from $98 and keeps a Buy rating on the shares.
Intellia Therapeutics: Buying The Path To Commercialization
Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...
Pharmaceutical Technology8d
CTX-131 by CRISPR Therapeutics for T-Cell Lymphomas: Likelihood of Approval
CTX-131 is under clinical development by CRISPR Therapeutics and currently in Phase II for T-Cell Lymphomas. According to GlobalData, Phase II drugs for T-Cell Lymphomas have a 29% phase transition ...